Pacira BioSciences Inc (PCRX)
25.48
-0.02
(-0.08%)
USD |
NASDAQ |
Apr 26, 09:50
Pacira BioSciences Price to Book Value: 1.362 for April 26, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 1.363 |
| April 24, 2024 | 1.384 |
| April 23, 2024 | 1.433 |
| April 22, 2024 | 1.395 |
| April 19, 2024 | 1.403 |
| April 18, 2024 | 1.395 |
| April 17, 2024 | 1.431 |
| April 16, 2024 | 1.436 |
| April 15, 2024 | 1.418 |
| April 12, 2024 | 1.434 |
| April 11, 2024 | 1.462 |
| April 10, 2024 | 1.487 |
| April 09, 2024 | 1.524 |
| April 08, 2024 | 1.522 |
| April 05, 2024 | 1.505 |
| April 04, 2024 | 1.518 |
| April 03, 2024 | 1.550 |
| April 02, 2024 | 1.524 |
| April 01, 2024 | 1.558 |
| March 28, 2024 | 1.562 |
| March 27, 2024 | 1.552 |
| March 26, 2024 | 1.524 |
| March 25, 2024 | 1.562 |
| March 22, 2024 | 1.532 |
| March 21, 2024 | 1.565 |
| Date | Value |
|---|---|
| March 20, 2024 | 1.604 |
| March 19, 2024 | 1.575 |
| March 18, 2024 | 1.565 |
| March 15, 2024 | 1.572 |
| March 14, 2024 | 1.564 |
| March 13, 2024 | 1.619 |
| March 12, 2024 | 1.633 |
| March 11, 2024 | 1.658 |
| March 08, 2024 | 1.679 |
| March 07, 2024 | 1.637 |
| March 06, 2024 | 1.609 |
| March 05, 2024 | 1.573 |
| March 04, 2024 | 1.560 |
| March 01, 2024 | 1.542 |
| February 29, 2024 | 1.588 |
| February 28, 2024 | 1.598 |
| February 27, 2024 | 1.595 |
| February 26, 2024 | 1.589 |
| February 23, 2024 | 1.605 |
| February 22, 2024 | 1.601 |
| February 21, 2024 | 1.586 |
| February 20, 2024 | 1.595 |
| February 16, 2024 | 1.553 |
| February 15, 2024 | 1.584 |
| February 14, 2024 | 1.561 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.362
Minimum
Apr 26 2024
6.938
Maximum
Sep 02 2020
3.795
Average
3.848
Median
Price to Book Value Benchmarks
| Dynavax Technologies Corp | 2.347 |
| Arbutus Biopharma Corp | 4.674 |
| Chimerix Inc | 0.4391 |
| Karyopharm Therapeutics Inc | -- |
| FibroGen Inc | -- |
Price to Book Value Related Metrics
| PE Ratio | 30.70 |
| PS Ratio | 2.066 |
| PEG Ratio | 0.1831 |
| Price to Free Cash Flow | 9.999 |
| Price | 25.48 |
| Earnings Yield | 3.26% |
| Market Cap | 1.185B |
| PEGY Ratio | 0.1831 |
| Operating PE Ratio | 15.97 |
| Normalized PE Ratio | 22.53 |